Roche maintains German investment despite industry pullbacks

09:00

Swiss pharmaceutical and diagnostics group Roche has confirmed that it will proceed with its planned investment in Germany, even as some competitors scale back spending in response to changes in national healthcare policy.

The company said it will continue investing approximately €600 million in a new diagnostics production facility in Penzberg, Germany. The project is one of Roche’s largest industrial investments in the country and remains scheduled for completion by 2027.

The announcement comes at a time when several major pharmaceutical companies are reassessing their presence in Germany. U.S. drugmaker Eli Lilly and Company recently reduced its planned investment in the country, while German group Boehringer Ingelheim cancelled a major expansion project, citing uncertainty linked to proposed healthcare cost-containment measures.

Roche acknowledged that the changing policy environment in Germany could influence future investment decisions. Company executives stated that increased regulatory uncertainty may affect long-term planning for research, development and production activities.

Despite these concerns, Roche emphasized its commitment to ongoing projects already in development. The Penzberg site is expected to strengthen the company’s diagnostics manufacturing capacity in Europe and support its long-term industrial strategy.

Industry observers note that Germany has traditionally been a key hub for pharmaceutical research and production. However, recent policy discussions aimed at controlling healthcare expenditure have raised concerns among some multinational companies about profitability and investment stability.

According to Roche representatives, the broader debate highlights the challenge of balancing cost control in healthcare systems with the need to maintain a strong and competitive life sciences industry. The company warned that policy uncertainty could discourage future investments if not addressed through clearer long-term frameworks.

As discussions continue in Germany’s legislative process, pharmaceutical companies are closely monitoring potential reforms that could shape the country’s attractiveness as a destination for high-value industrial investment.